22RV1 Cells
Product number:
305037
General information
Description | The 22Rv1 cell line is a human prostate carcinoma cell line that was established from a xenograft initiated by the inoculation of a hormone-refractory prostate cancer cell line, CWR22, into athymic nude mice. The CWR22 xenograft was derived from a primary prostate carcinoma. Upon regression after castration and subsequent relapse, the 22Rv1 cell line was established from the relapsed tumor, which exhibited androgen-independent growth. 22Rv1 cells express the androgen receptor (AR) and prostate-specific antigen (PSA), essential markers in prostate cancer research and therapeutic targeting. Notably, this cell line contains a variant form of the AR known as AR-V7. This splice variant lacks the ligand-binding domain, enabling it to remain constitutively active and contribute to the androgen-independent proliferation of 22Rv1 cells, a critical aspect of castration-resistant prostate cancer (CRPC). The 22Rv1 cell line is extensively used to investigate the mechanisms underlying the transition from androgen-dependent to androgen-independent prostate cancer growth, a key challenge in the treatment of advanced prostate cancer. 22Rv1 cells have facilitated significant advancements in understanding the molecular biology of CRPC, including the role of AR variants in resistance to androgen deprivation therapy (ADT) and the development of novel therapeutic strategies aimed at overcoming this resistance. In summary, the 22Rv1 cell line, serves as a critical model for studying CRPC. Exhibiting androgen-independent growth, these cells express key prostate cancer markers such as AR and PSA, and notably contain the AR-V7 variant, which is constitutively active due to the absence of the ligand-binding domain. The 22Rv1 cell line's unique properties make it invaluable for exploring the transition from androgen-dependent to independent growth in prostate cancer, and thereby aid in the development of new therapeutic approaches to tackle advanced stages of the disease. |
---|---|
Organism | Human |
Tissue | Prostate |
Disease | Prostate carcinoma |
Synonyms | 22Rv1, 22Rv-1, 22rV1, CWR-22rv1, CWR22-Rv1, CWR22R-V1, CWR22-R1, CWR22Rv1, CWR22R |
Characteristics
Age | Adult |
---|---|
Gender | Male |
Ethnicity | European |
Morphology | Epithelial |
Growth properties | Adherent |
Identifiers / Biosafety / Citation
Citation | 22RV1 (Cytion catalog number 305037) |
---|---|
Biosafety level | 1 (2 when used for genetic engineering) |
Expression / Mutation
Antigen expression | Prostate-specific antigen (PSA) |
---|---|
Tumorigenic | Yes |
Handling
Culture Medium | RPMI 1640, w: 2.1 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
---|---|
Medium supplements | Supplement the medium with 10% FBS |
Passaging solution | Accutase |
Doubling time | 40 to 60 hours |
Subculturing | Remove the old medium from the adherent cells and wash them with PBS that lacks calcium and magnesium. For T25 flasks, use 3-5 ml of PBS, and for T75 flasks, use 5-10 ml. Then, cover the cells completely with Accutase, using 1-2 ml for T25 flasks and 2.5 ml for T75 flasks. Let the cells incubate at room temperature for 8-10 minutes to detach them. After incubation, gently mix the cells with 10 ml of medium to resuspend them, then centrifuge at 300xg for 3 minutes. Discard the supernatant, resuspend the cells in fresh medium, and transfer them into new flasks that already contain fresh medium. |
Split ratio | 1:3 to 1:6 |
Fluid renewal | 2 to 3 times per week |
Freeze medium | CM-1 (Cytion catalog number 800100) or CM-ACF (Cytion catalog number 806100) |
Handling of cryopreserved cultures | 22RV1 cells are shipped in a deep-frozen state on dry ice. Upon receipt, confirm that the vial remains frozen. For storage, place the cryovial immediately at temperatures below -150 degrees. If you plan to culture the cells immediately, swiftly thaw the vial by shaking it in a 37 degrees water bath with clean water and an antimicrobial agent for 40-60 seconds. Remove the vial once a small ice clump persists, ensuring it remains cold. Proceed with all subsequent steps under aseptic conditions. In a sterile flow hood, disinfect the cryovial with 70% ethanol. Then, gently open the vial and transfer the cell suspension into a 15 ml centrifuge tube pre-filled with 8 ml of room temperature culture medium. Gently mix the cells. For cell separation, centrifuge at 300 x g for 3 minutes and dispose of the supernatant. Skipping centrifugation is optional, although any residual freezing medium should be removed after 24 hours. Resuspend the pellet gently in 10 ml of fresh culture medium and divide between two T25 culture flasks. Follow the subculture protocol for subsequent steps. |
Quality control / Genetic profile / HLA
Sterility | Mycoplasma contamination is rigorously excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
---|---|
STR profile |
Amelogenin: x,y
CSF1PO: 10,11
D13S317: 9,12
D16S539: 12
D5S818: 11,13
D7S820: 9,10,11
TH01: 6,9.3
TPOX: 8
vWA: 15,21
D3S1358: 15
D21S11: 30
D18S51: 11,13
Penta E: 5,13
Penta D: 9,12
D8S1179: 13,14
FGA: 19,20,23
D1S1656: 17,18,19
D6S1043: 16
D2S1338: 17,18
D12S391: 18,25
D19S433: 13,14
|